Archive | 2017 Rayno Biopharmaceuticals Portfolio

The Rayno Biopharmaceuticals Portfolio are up to date picks for 2017.  We are in a recovering bear market for biotechnology stocks that appears to have bottomed with buy signals given early in 2017.

Healthcare and Biotech for Relative Safety: ALXN,REGN,OPTR,SGEN

A Place to Hide from Volatility Today was not as bad as early futures and European markets would portend. The S&P cut its losses to 0.74% and the NASDAQ was down only 0.26%. But as we recommended last month the healthcare sector looks good for relative safety. Drug stocks that pay dividends and large cap […]

Continue Reading 0

Rayno Life Science Portfolio 2011 H1 Update-Biopharm Big Winners:BIIB, CBST, REGN, SGEN

2011 A Huge Year for Life Science Investing As of mid-year the Rayno Life Science Biopharmaceutical Portfolio was up over 20% beating most  ETF’s and Life Science mutual funds. Our two recommended biotech ETF’s for balancing and overweighting were FBT up 13.3% and IBB up 15.3%. Returns could have been much higher with rebalancing strategies […]

Continue Reading 0

Rayno Biopharma Portfolio: Update 4/11,6/11, and 11/11,21/11

11/18 Added Dendreon (DNDN) at $8.00 level.IBB is preferred biotech ETF. 11/15/11 Comments: Under review: ImmunoGen (IMGN) Dropped FBT an ETF in favor of  IBB or possibly XBI. For bullish equity allocation in Tech and Biotech use QQQ. 6/20/11 NASDAQ (2632) Market stabilizing after 7% correction.QQQ down <1%. IBB up 10% YTD. Mid-cap biopharms are up […]

Continue Reading 0